With Dilon Devices entering a phase of commercial growth and expansion of its RFST platform, Dilon CEO Lori Chmura and Chairman of the Board of Directors Amos Goren started the year off by attending the 37th Annual J.P. Morgan Healthcare Conference on January 7-10. This conference is considered to be the largest and most informative healthcare investment symposium in the industry.
The J.P. Morgan Healthcare Conference brings together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community to discuss the healthcare climate for the year. Dilon took this opportunity to speak with investors about their Radio-Frequency (RF) Spectroscopy technology applications in cancer identification.
This meeting comes shortly after Lori gave a presentation at the 2018 Canaccord Genuity Medical Technologies and Diagnostics Forum, detailing how Dilon is revolutionizing tissue characterization technology. Visit the investor page on Dilon’s website to view the full presentation.
Dilon strives to improve the standard of care with the expansion of their RF spectroscopy platform. This proprietary technology has been utilized in over 10,000 patients and the MarginProbe device has been shown to reduce re-excision rates in lumpectomy surgery by 79%. Dune has also recently reached the halfway point in their Post-Approval Study for MarginProbe, with over 250 patients enrolled in the third randomized controlled trial. This study is expected to be completed in August 2019.
Dilon Devices was happy to be a part of the 37th Annual J.P. Morgan Healthcare Conference and look forward to the opportunities that will arise from attending this global healthcare event.
If you would like to know more about our business and its potential, contact email@example.com.